FDA Removes Contraindication for Use of Bracco’s Lumason

January 11, 2017

The FDA informed New Jersey–based Bracco Diagnostics that it has removed the contraindication for Lumason, an ultrasound contrast agent for use in patients with cardiac shunts.

The agency has determined that the benefits from the use of Lumason in patients with cardiac shunts may outweigh the risk for systemic embolization. — Cynthia Jessup

View today's stories